FDA grants Priority Review and European Medicines Agency accepts regulatory submission for abrocitinib as treatment of moderate to severe atopic dermatitis

Regulatory filings for this oral once-daily JAK1 inhibitor were based on JADE MONO-1, JADE MONO-2, JADE COMPARE trials, across which abrocitinib demonstrated statistically superior improvements in skin clearance, disease extent, and severity, and itch vs placebo.

Source:

Biospace Inc.